VK2735 is investigational GIP/GLP-1 dual agonist, injection and pill (Viking Therapeutics). VK2735 is Viking Therapeutics' experimental weight-management drug, tested as a weekly injection and as a daily pill. It acts on the same two receptors as tirzepatide.
Education only. Not medical advice. No dosing information.
Status (verified Oct 29, 2026): Investigational: Phase 3 VANQUISH (results expected 2027); oral Phase 3 started Oct 2026; not approved. Source: Viking Q3 2026 update: VANQUISH fully enrolled; oral Phase 3 started
Evidence tier: Phase 2 trials; Phase 3 ongoing
Get alerts on legal status changes ->
What it is
VK2735 is Viking Therapeutics' experimental weight-management drug, tested as a weekly injection and as a daily pill. It acts on the same two receptors as tirzepatide.
How it works
It activates both GIP and GLP-1 receptors to reduce appetite and improve blood sugar.
What it's researched for
Obesity and overweight, with and without type 2 diabetes.
Where it shows up on Peptide Horizon
Regulatory and research timeline
- 2025-06: VANQUISH-2 Phase 3 starts (source)
- 2026-03: Phase 2 VENTURE results published (Obesity) (source)
- 2026-10: Viking Q3 2026 update: VANQUISH fully enrolled; oral Phase 3 started (source)
Key trials and studies
FAQ
Is VK2735 FDA approved?
No. Phase 3 results are expected in 2027.
VK2735 vs tirzepatide?
Both activate GIP and GLP-1 receptors; tirzepatide is approved, VK2735 is in trials.
Is there a VK2735 pill?
Yes, an oral version entered Phase 3 in October 2026.
Related peptides
- tirzepatide FDA status and research
- maridebart-cafraglutide FDA status and research
- retatrutide FDA status and research
Get alerts on legal status changes
Free email alerts when the FDA, HHS or another regulator changes the status of VK2735 or other peptides. Get alerts ->
Sources
- https://pubmed.ncbi.nlm.nih.gov/41508550
- https://clinicaltrials.gov/study/NCT07104383
- https://ir.vikingtherapeutics.com/2026-10-28-Viking-Therapeutics-Reports-Third-Quarter-2026-Financial-Results-and-Provides-Corporate-Update
Editorial review - Last reviewed Oct 29, 2026